Corporate Headquarters
505 Lomas Santa Fe Drive
Suite 270
Solana Beach, CA 92075

(858)345-1494 Tel.

Investor Relations :: Overview

Stock price graph

Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. EVK-001 is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration.


Nov 13, 2014 at 4:30 PM ET
Evoke Pharma Third Quarter 2014 Conference Call

Sep 22, 2014 Interview with Evoke Pharma CBO Matt D'Onofrio

Aug 13, 2014
Evoke Pharma Second Quarter 2014 Conference Call

Presentations and Posters

Evoke Pharma Presentation at the LD Micro Conference. December 4, 2014 PDF 1.8 MB  
Evoke Pharma Investor Presentation PDF 1.8 MB  
Texas Tech University Health Sciences Center PDF 622.5 KB  

Recent Releases

Dec 2, 2014
Evoke Pharma's EVK-001 Showed No QT Prolongation in Thorough ECG (TQT) Study

Nov 25, 2014
Evoke Pharma to Present at LD Micro Conference

View all releases »